ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

1:45PM-2:00PM: Abstract Number: 2582

Inflammatory Cell Death and Impaired Efferocytosis Drive Monocyte and Macrophage Dysfunction in VEXAS Syndrome.

Abstracts: Innate Immunity (2579–2584)

1:45PM-2:00PM: Abstract Number: 2576

Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH) Study: Anti-inflammatory cytokine signals related to decreased arthritis disease activity over time

Abstracts: Infection-related Rheumatic Disease (2573–2578)

1:45PM-2:00PM: Abstract Number: 2588

Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

2:00PM-2:15PM: Abstract Number: 2583

CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis

Abstracts: Innate Immunity (2579–2584)

2:00PM-2:15PM: Abstract Number: 2601

Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

2:00PM-2:15PM: Abstract Number: 2577

Duration of SARS-CoV-2 Viral Shedding After Acute Infection in Patients with Rheumatic Diseases Using B Cell Depletion or Tumor Necrosis Factor Inhibitors

Abstracts: Infection-related Rheumatic Disease (2573–2578)

2:00PM-2:15PM: Abstract Number: 2595

Impact of Different Types of Physical Activity on Bone Health in Patients with Inflammatory Rheumatic Diseases: a Cross-Sectional Analysis from a Prospective Cohort Study

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

2:00PM-2:15PM: Abstract Number: 2589

Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

2:00PM-2:15PM: Abstract Number: 2571

Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring

Abstracts: Epidemiology & Public Health II (2567–2572)

2:15PM-2:30PM: Abstract Number: 2578

Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases

Abstracts: Infection-related Rheumatic Disease (2573–2578)

2:15PM-2:30PM: Abstract Number: 2602

Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus

Abstracts: Systemic Lupus Erythematosus – Etiology and Pathogenesis (2597–2602)

2:15PM-2:30PM: Abstract Number: 2572

Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program

Abstracts: Epidemiology & Public Health II (2567–2572)

2:15PM-2:30PM: Abstract Number: 2596

Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596)

2:15PM-2:30PM: Abstract Number: 2584

Spatially Resolved Transcriptomics Reveal Macrophage Heterogeneity in Giant Cell Arteritis

Abstracts: Innate Immunity (2579–2584)

2:15PM-2:30PM: Abstract Number: 2590

Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women

Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science (2585–2590)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].